To include your compound in the COVID-19 Resource Center, submit it here.

GAO unmasks drug price index

WASHINGTON - A General Accounting Office investigation of government drug price monitoring has raised doubt about the value of the official drug price inflation measure as a policy-making tool.

The GAO's report last week, "Prescription Drug Prices: Official Index Overstates Producer Price Inflation," not only concludes that the Bureau of Labor Statistics' PPI-Drugs Index overstates prescription drug inflation, but also is unsuitable for relating the benefit of drugs to prices.

The BLS measure, the official wholesale index of U.S. drug prices,

Read the full 793 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers